Equities analysts expect that Evogene Ltd (NYSE:EVGN) will post earnings per share (EPS) of ($0.13) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Evogene’s earnings. Evogene posted earnings per share of ($0.18) in the same quarter last year, which suggests a positive year over year growth rate of 27.8%. The company is scheduled to issue its next earnings results before the market opens on Thursday, August 10th.
On average, analysts expect that Evogene will report full year earnings of ($0.68) per share for the current year. For the next year, analysts expect that the firm will report earnings of ($0.02) per share. Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that follow Evogene.
Evogene (NYSE:EVGN) last posted its earnings results on Wednesday, May 17th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.18) by $0.01. Evogene had a negative net margin of 235.47% and a negative return on equity of 18.60%. The business had revenue of $0.72 million for the quarter.
A number of large investors have recently modified their holdings of EVGN. UBS Group AG raised its stake in shares of Evogene by 10.1% in the first quarter. UBS Group AG now owns 1,052,537 shares of the biotechnology company’s stock worth $5,628,000 after buying an additional 96,527 shares during the period. Bank of America Corp DE raised its stake in shares of Evogene by 5.3% in the first quarter. Bank of America Corp DE now owns 841,552 shares of the biotechnology company’s stock worth $4,500,000 after buying an additional 42,532 shares during the period. Canada Pension Plan Investment Board raised its stake in shares of Evogene by 142.9% in the second quarter. Canada Pension Plan Investment Board now owns 680,000 shares of the biotechnology company’s stock worth $3,414,000 after buying an additional 400,000 shares during the period. Goldman Sachs Group Inc. raised its stake in shares of Evogene by 59.6% in the first quarter. Goldman Sachs Group Inc. now owns 606,962 shares of the biotechnology company’s stock worth $3,246,000 after buying an additional 226,778 shares during the period. Finally, JPMorgan Chase & Co. raised its stake in shares of Evogene by 53.4% in the first quarter. JPMorgan Chase & Co. now owns 245,425 shares of the biotechnology company’s stock worth $4,079,000 after buying an additional 85,425 shares during the period. 29.88% of the stock is owned by institutional investors and hedge funds.
Shares of Evogene (NYSE:EVGN) traded up 3.99% during midday trading on Wednesday, reaching $4.95. The company had a trading volume of 12,550 shares. Evogene has a 1-year low of $4.60 and a 1-year high of $7.09. The stock’s market capitalization is $126.85 million. The firm’s 50 day moving average price is $5.09 and its 200-day moving average price is $5.17.
About Evogene
Evogene Ltd. (Evogene) is a biotechnology company for the improvement of crop productivity. The Company is engaged in developing seed traits for improved yield and abiotic stress tolerance, seed traits for biotic stress resistance, herbicides and bio-stimulants. The Company operates a seed business under its subsidiary Evofuel Ltd.
Get a free copy of the Zacks research report on Evogene (EVGN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Evogene Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene Ltd and related companies with MarketBeat.com's FREE daily email newsletter.
